靖因药业

Jingyin Biopharma is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of small interfering RNA (siRNA) therapeutics. The company leverages its proprietary GalNAc-siRNA delivery platform to target chronic diseases with high unmet medical needs, particularly in the cardiovascular, metabolic, and hematological fields. Its lead program, JY-001, is an ANGPTL3-targeting siRNA designed for the treatment of hypertriglyceridemia and is currently in clinical development. Jingyin Biopharma was founded by industry veterans with significant experience in oligonucleotide drug development and has secured substantial venture capital funding to advance its modular RNAi pipeline. The company aims to provide long-acting, highly specific treatments that improve patient compliance and clinical outcomes for prevalent chronic conditions.